DAFNA Capital Management
Latest statistics and disclosures from DAFNA Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, STXS, RVMD, CYTK, MRUS, and represent 31.35% of DAFNA Capital Management's stock portfolio.
- Added to shares of these 10 stocks: LXEO, BPMC, IDYA, ASND, GPCR, ALLO, DAWN, BNTX, GRAL, BDTX.
- Started 6 new stock positions in Biomx, VSTM, LXEO, BDTX, BNTX, GRAL.
- Reduced shares in these 10 stocks: MORF (-$7.9M), XBI, VKTX, SNDX, TSVT, EWTX, BHVN, TRML, SPRY, MDWD.
- Sold out of its positions in MORF, ORIC, PRCT, SYRS, TERN.
- DAFNA Capital Management was a net seller of stock by $-19M.
- DAFNA Capital Management has $423M in assets under management (AUM), dropping by 1.13%.
- Central Index Key (CIK): 0001389933
Tip: Access up to 7 years of quarterly data
Positions held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 84 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr S&p Biotech Etf Etf (XBI) | 9.4 | $40M | -9% | 402k | 98.80 |
|
| Stereotaxis Com New (STXS) | 6.6 | $28M | 14M | 2.04 |
|
|
| Revolution Medicines (RVMD) | 5.5 | $24M | 518k | 45.35 |
|
|
| Cytokinetics Com New (CYTK) | 5.0 | $21M | 398k | 52.80 |
|
|
| Merus N V (MRUS) | 4.9 | $21M | 413k | 49.96 |
|
|
| AtriCure (ATRC) | 4.3 | $18M | 642k | 28.04 |
|
|
| Ideaya Biosciences (IDYA) | 3.5 | $15M | +11% | 471k | 31.68 |
|
| Ishares Nasdaq Biotech Indx Etf (IBB) | 3.5 | $15M | 103k | 145.60 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 3.2 | $13M | +10% | 90k | 149.31 |
|
| Axogen (AXGN) | 3.1 | $13M | 936k | 14.02 |
|
|
| Blueprint Medicines (BPMC) | 2.7 | $11M | +16% | 122k | 92.50 |
|
| Xenon Pharmaceuticals (XENE) | 2.5 | $11M | 274k | 39.37 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 2.5 | $11M | +12% | 750k | 13.93 |
|
| Syndax Pharmaceuticals (SNDX) | 2.4 | $10M | -19% | 527k | 19.25 |
|
| Biohaven (BHVN) | 2.2 | $9.4M | -14% | 187k | 49.97 |
|
| Tandem Diabetes Care Com New (TNDM) | 2.0 | $8.7M | 204k | 42.41 |
|
|
| Kalvista Pharmaceuticals (KALV) | 2.0 | $8.4M | -10% | 724k | 11.58 |
|
| Neurocrine Biosciences (NBIX) | 1.9 | $8.0M | -2% | 70k | 115.22 |
|
| Kura Oncology (KURA) | 1.9 | $8.0M | -3% | 408k | 19.54 |
|
| Viking Therapeutics (VKTX) | 1.9 | $8.0M | -33% | 126k | 63.31 |
|
| Edgewise Therapeutics (EWTX) | 1.4 | $6.1M | -21% | 228k | 26.69 |
|
| Urogen Pharma (URGN) | 1.4 | $5.8M | -2% | 459k | 12.70 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.2 | $5.1M | -5% | 667k | 7.60 |
|
| Ascendis Pharma A/s Note 2.250% 4/0 (Principal) | 1.1 | $4.7M | 4.0M | 1.17 |
|
|
| Dex (DXCM) | 1.0 | $4.4M | 66k | 67.04 |
|
|
| Keros Therapeutics (KROS) | 1.0 | $4.3M | +8% | 74k | 58.07 |
|
| Alector (ALEC) | 1.0 | $4.3M | 913k | 4.66 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 0.9 | $3.9M | 257k | 15.29 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 0.9 | $3.7M | 130k | 28.79 |
|
|
| Insulet Corporation (PODD) | 0.9 | $3.7M | 16k | 232.75 |
|
|
| Alkermes SHS (ALKS) | 0.8 | $3.4M | 121k | 27.99 |
|
|
| Larimar Therapeutics (LRMR) | 0.8 | $3.2M | -22% | 494k | 6.55 |
|
| Perspective Therapeutics Com New (CATX) | 0.7 | $3.1M | 230k | 13.35 |
|
|
| 2seventy Bio Common Stock (TSVT) | 0.7 | $3.0M | -40% | 630k | 4.72 |
|
| Acelyrin (SLRN) | 0.7 | $3.0M | -13% | 603k | 4.93 |
|
| Allogene Therapeutics (ALLO) | 0.7 | $2.9M | +73% | 1.1M | 2.80 |
|
| Aquestive Therapeutics (AQST) | 0.7 | $2.9M | +11% | 590k | 4.98 |
|
| Century Therapeutics (IPSC) | 0.7 | $2.9M | 1.7M | 1.71 |
|
|
| Astria Therapeutics (ATXS) | 0.7 | $2.8M | -7% | 254k | 11.01 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.7 | $2.8M | 122k | 22.63 |
|
|
| Stoke Therapeutics (STOK) | 0.6 | $2.5M | 207k | 12.29 |
|
|
| Brainsway Sponsored Ads (BWAY) | 0.5 | $2.3M | -15% | 251k | 9.24 |
|
| Lexeo Therapeutics (LXEO) | 0.5 | $2.3M | NEW | 251k | 9.04 |
|
| Accuray Incorporated (ARAY) | 0.5 | $2.2M | 1.2M | 1.80 |
|
|
| Silverback Therapeutics (SPRY) | 0.5 | $2.2M | -38% | 148k | 14.50 |
|
| Inogen (INGN) | 0.5 | $2.0M | 209k | 9.70 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.5 | $1.9M | -2% | 120k | 15.99 |
|
| Mineralys Therapeutics (MLYS) | 0.4 | $1.8M | +23% | 147k | 12.11 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.4 | $1.8M | +40% | 487k | 3.63 |
|
| Immatics Nv SHS (IMTX) | 0.4 | $1.7M | 145k | 11.41 |
|
|
| Iteos Therapeutics (ITOS) | 0.4 | $1.6M | +11% | 162k | 10.21 |
|
| Proqr Therapeutics N V Shs Euro (PRQR) | 0.4 | $1.6M | 906k | 1.82 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.4 | $1.5M | 243k | 6.30 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.4 | $1.5M | +580% | 34k | 43.89 |
|
| Immunovant (IMVT) | 0.4 | $1.5M | +8% | 52k | 28.51 |
|
| Regulus Therapeutics (RGLS) | 0.3 | $1.4M | 895k | 1.57 |
|
|
| Gossamer Bio (GOSS) | 0.3 | $1.4M | 1.4M | 0.99 |
|
|
| Lineage Cell Therapeutics In (LCTX) | 0.3 | $1.2M | 1.4M | 0.91 |
|
|
| Mediwound Shs New (MDWD) | 0.3 | $1.2M | -48% | 65k | 18.06 |
|
| Sutro Biopharma (STRO) | 0.3 | $1.1M | 330k | 3.46 |
|
|
| Polypid (PYPD) | 0.3 | $1.1M | +66% | 309k | 3.44 |
|
| Nyxoah S A SHS (NYXH) | 0.2 | $1.0M | 108k | 9.55 |
|
|
| Biontech Se Sponsored Ads (BNTX) | 0.2 | $1.0M | NEW | 8.5k | 118.77 |
|
| Adicet Bio (ACET) | 0.2 | $864k | 600k | 1.44 |
|
|
| Compugen Ord (CGEN) | 0.2 | $809k | -3% | 447k | 1.81 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.2 | $787k | -7% | 112k | 7.00 |
|
| Sage Therapeutics (SAGE) | 0.2 | $781k | -6% | 108k | 7.22 |
|
| Grail (GRAL) | 0.2 | $672k | NEW | 49k | 13.76 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.2 | $643k | 204k | 3.15 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.1 | $544k | NEW | 125k | 4.35 |
|
| Tourmaline Bio (TRML) | 0.1 | $491k | -74% | 19k | 25.71 |
|
| Biomx Com New | 0.1 | $409k | NEW | 401k | 1.02 |
|
| Masimo Corporation (MASI) | 0.1 | $400k | 3.0k | 133.33 |
|
|
| Verastem Com New (VSTM) | 0.1 | $382k | NEW | 128k | 2.99 |
|
| Aprea Therapeutics Com New (APRE) | 0.1 | $377k | 137k | 2.75 |
|
|
| Foghorn Therapeutics (FHTX) | 0.1 | $351k | -10% | 38k | 9.31 |
|
| Neurogene (NGNE) | 0.1 | $326k | -29% | 7.8k | 41.96 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $324k | 341k | 0.95 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.1 | $306k | -77% | 27k | 11.44 |
|
| Neuronetics (STIM) | 0.1 | $238k | 314k | 0.76 |
|
|
| Compass Therapeutics (CMPX) | 0.1 | $215k | 117k | 1.84 |
|
|
| Nevro (NVRO) | 0.1 | $212k | +35% | 38k | 5.59 |
|
| Spero Therapeutics (SPRO) | 0.0 | $168k | 125k | 1.34 |
|
|
| Karyopharm Therapeutics (KPTI) | 0.0 | $160k | 193k | 0.83 |
|
Past Filings by DAFNA Capital Management
SEC 13F filings are viewable for DAFNA Capital Management going back to 2010
- DAFNA Capital Management 2024 Q3 filed Nov. 14, 2024
- DAFNA Capital Management 2024 Q2 filed Aug. 14, 2024
- DAFNA Capital Management 2024 Q1 filed May 15, 2024
- DAFNA Capital Management 2023 Q4 filed Feb. 14, 2024
- DAFNA Capital Management 2023 Q3 filed Nov. 14, 2023
- DAFNA Capital Management 2023 Q2 filed Aug. 14, 2023
- DAFNA Capital Management 2023 Q1 filed May 15, 2023
- DAFNA Capital Management 2022 Q4 filed Feb. 14, 2023
- DAFNA Capital Management 2022 Q3 filed Nov. 14, 2022
- DAFNA Capital Management 2022 Q2 filed Aug. 15, 2022
- DAFNA Capital Management 2022 Q1 filed May 16, 2022
- DAFNA Capital Management 2021 Q4 filed Feb. 14, 2022
- DAFNA Capital Management 2021 Q3 filed Nov. 15, 2021
- DAFNA Capital Management 2021 Q2 filed Aug. 16, 2021
- DAFNA Capital Management 2021 Q1 filed May 17, 2021
- DAFNA Capital Management 2020 Q4 filed Feb. 16, 2021